---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-024997"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-06-12T11:10:43+00:00"
generated_at: "2026-06-12T11:15:13.398714+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals closes sale of rare pediatric disease PRV for $180M

## Summary
- Closed sale of Rare Pediatric Disease PRV to large pharma for gross proceeds of $180M.
- PRV was granted by FDA in March 2026 with approval of KRESLADI for severe LAD-I.
- Pro forma cash, cash equivalents, and investments total ~$322.6M, extending runway into Q2 2028.
- Previously reported cash of $144.4M as of March 31, 2026.

## SEC filing metadata
- accession: 0001140361-26-024997
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-06-12T11:10:43+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/0001140361-26-024997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/ef20076119_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-024997
- JSON: https://secwatch.observer/filing/0001140361-26-024997.json
- Plain text: https://secwatch.observer/filing/0001140361-26-024997.txt

## Key facts
- M&A Transactions
  ROCKET PHARMACEUTICALS, INC. completed a disposition involving a large pharmaceutical company for $180.0 million (closed 2026-06-10).
  - Action: disposition
  - Counterparty: a large pharmaceutical company
  - Consideration: $180.0 million
  - Closing: 2026-06-10
  source text: Sale was completed pursuant to the terms of an asset purchase agreement, dated April 26, 2026 (the “PRV APA”). Pursuant to the PRV APA, the Company received gross proceeds of $180.0 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV APA does not purport to be complete and is subject to, and qualified in its entirety, by
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/0001140361-26-024997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.